Kristof Baete
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristof Baete has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Christophe M. Deroose
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
3 shared publications - Georg Schramm
Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
3 shared publications - Koen Van Laere
Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium
3 shared publications - Michel Koole
Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
3 shared publications - Ahmadreza Rezaei
Nuclear Medicine, KU Leuven, UZ Herestraat 49 - box 7003, Leuven, 3000, BELGIUM
2 shared publications An De Crop
Nuclear Medicine, AZ Delta, Roeselare, Belgium
2 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Multicenter comparison of radionuclide calibrators and SPECT/CT protocols for quantitative 177Lu imaging in clinical practice
Purpose: Following the clinical success of $$^{177}\text{Lu}$$ -based therapies for neuroendocrine tumors and prostate cancer, accurate quantification of $$^{177}\text{Lu}$$ using radionuclide calibrators (RNCs) and SPECT/CT is gaining importance as prerequisite for accurate treatment delivery and dosimetry. However, the lack of standardization can introduce inter-system variability, compromising multi-center clinical trials. This study aimed to assess the accuracy and variability of $$^{177}\text{Lu}$$ measurements using RNCs and SPECT/CT across different systems and hospitals. Methods: A uniform cylindrical phantom and a NEMA phantom with hot spheres were prepared using traceable activities and imaged at 8 different hospitals using 13 SPECT/CT systems (9 conventional and 4 3D CZT). Acquisitions and reconstructions were performed using both site-specific and standardized protocols. The cylindrical phantom images were used to evaluate the system calibration and establish image calibration factors (ICFs), the NEMA images to evaluate effective resolution by calculating recovery coefficients (RCs). In parallel, two vials were measured to test RNC accuracy. Results: RNC measurements differed up to 11% between centers, while SPECT quantification of the cylindrical phantom differed up to 20%. While ICFs were consistent for systems of the same type, image quality varied strongly when using clinical protocols (36% difference in RCs in the largest sphere). Standardized reconstruction reduced variability in RCs for each system type (maximum 12% difference), regardless of acquisition protocol, but differences between system types persisted when standardizing acquisition and reconstruction (33% difference). Conclusion: Current $$^{177}\text{Lu}$$ measurement practices yield significant variability in quantification and image quality. Harmonization efforts should prioritize standardized calibration and reconstruction protocols to improve multicenter reproducibility of quantitative $$^{177}\text{Lu}$$ -SPECT/CT.- 8 May 2026
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Open AccessMulticenter comparison of radionuclide calibrators and SPECT/CT protocols for quantitative 177Lu imaging in clinical practice
Purpose: Following the clinical success of $$^{177}\text{Lu}$$ -based therapies for neuroendocrine tumors and prostate cancer, accurate quantification of $$^{177}\text{Lu}$$ using radionuclide calibrators (RNCs) and SPECT/CT is gaining importance as prerequisite for accurate treatment delivery and dosimetry. However, the lack of standardization can introduce inter-system variability, compromising multi-center clinical trials. This study aimed to assess the accuracy and variability of $$^{177}\text{Lu}$$ measurements using RNCs and SPECT/CT across different systems and hospitals. Methods: A uniform cylindrical phantom and a NEMA phantom with hot spheres were prepared using traceable activities and imaged at 8 different hospitals using 13 SPECT/CT systems (9 conventional and 4 3D CZT). Acquisitions and reconstructions were performed using both site-specific and standardized protocols. The cylindrical phantom images were used to evaluate the system calibration and establish image calibration factors (ICFs), the NEMA images to evaluate effective resolution by calculating recovery coefficients (RCs). In parallel, two vials were measured to test RNC accuracy. Results: RNC measurements differed up to 11% between centers, while SPECT quantification of the cylindrical phantom differed up to 20%. While ICFs were consistent for systems of the same type, image quality varied strongly when using clinical protocols (36% difference in RCs in the largest sphere). Standardized reconstruction reduced variability in RCs for each system type (maximum 12% difference), regardless of acquisition protocol, but differences between system types persisted when standardizing acquisition and reconstruction (33% difference). Conclusion: Current $$^{177}\text{Lu}$$ measurement practices yield significant variability in quantification and image quality. Harmonization efforts should prioritize standardized calibration and reconstruction protocols to improve multicenter reproducibility of quantitative $$^{177}\text{Lu}$$ -SPECT/CT. - 26 February 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (4) , 045019
Strengths and weaknesses of energy-based scatter estimation using three basis functions
Objective. Quantitative imaging in positron emission tomography (PET) requires accurate, precise, and efficient scatter correction techniques. Conventional scatter estimation typically relies on single-scatter simulation (SSS) combined with a tail-fitting strategy. However, the accuracy of tail-fitted SSS is limited, for example, by mismatches between the attenuation image and the PET emission data or by the presence of activity outside the field of view (FOV). These shortcomings can be addressed using energy-based scatter estimation (EBSE), as recently proposed by Efthimiou et al (2022 Phys. Med. Biol. 67 095010); Hamill et al (2024 Med. Phys. 51 54–69). The aim of this work is to (1) investigate the accuracy of EBSE by accounting for the line-of-response dependence of the energy spectrum of unscattered photons, (2) improve the computational speed of EBSE through better initialization and a more efficient optimization algorithm, and (3) validation and characterization of EBSE using a three-basis model across different object sizes and activity distributions. Approach. The proposed improved EBSE method models the energy spectrum of scattered photons with two probability density functions (PDFs), and incorporates a position-dependent (local) energy PDF for unscattered photons. These energy PDFs form the basis of a forward model—a linear nine-parameter model —used for scatter estimation based on 2D energy histograms. The performance of the EBSE was evaluated using GATE Monte Carlo simulations and a NEMA phantom acquisition on a GE SIGNA PET/MR scanner. Furthermore, we assessed the stability of EBSE across the forward model by varying the number of counts in the 2D energy histograms via data mashing. Main results. EBSE reduced artifacts caused by out-of-FOV activity and demonstrated performance comparable to tail-fitted SSS in other regions. Incorporating a local unscattered PDF improved off-center quantification, and NEGML with improved initialization plus histogram down-sampling substantially reduced computation without compromising accuracy. Limitations were observed: the proposed basis-function model for scattered-photon energy spectra lacks full generality across attenuation and activity distributions. Significance. This study improves the accuracy and computational efficiency of EBSE for clinically realistic activity and attenuation conditions, while clarifying scattered basis function limitations.
- 26 February 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (4) , 045019
Strengths and weaknesses of energy-based scatter estimation using three basis functions
Objective. Quantitative imaging in positron emission tomography (PET) requires accurate, precise, and efficient scatter correction techniques. Conventional scatter estimation typically relies on single-scatter simulation (SSS) combined with a tail-fitting strategy. However, the accuracy of tail-fitted SSS is limited, for example, by mismatches between the attenuation image and the PET emission data or by the presence of activity outside the field of view (FOV). These shortcomings can be addressed using energy-based scatter estimation (EBSE), as recently proposed by Efthimiou et al (2022 Phys. Med. Biol. 67 095010); Hamill et al (2024 Med. Phys. 51 54–69). The aim of this work is to (1) investigate the accuracy of EBSE by accounting for the line-of-response dependence of the energy spectrum of unscattered photons, (2) improve the computational speed of EBSE through better initialization and a more efficient optimization algorithm, and (3) validation and characterization of EBSE using a three-basis model across different object sizes and activity distributions. Approach. The proposed improved EBSE method models the energy spectrum of scattered photons with two probability density functions (PDFs), and incorporates a position-dependent (local) energy PDF for unscattered photons. These energy PDFs form the basis of a forward model—a linear nine-parameter model —used for scatter estimation based on 2D energy histograms. The performance of the EBSE was evaluated using GATE Monte Carlo simulations and a NEMA phantom acquisition on a GE SIGNA PET/MR scanner. Furthermore, we assessed the stability of EBSE across the forward model by varying the number of counts in the 2D energy histograms via data mashing. Main results. EBSE reduced artifacts caused by out-of-FOV activity and demonstrated performance comparable to tail-fitted SSS in other regions. Incorporating a local unscattered PDF improved off-center quantification, and NEGML with improved initialization plus histogram down-sampling substantially reduced computation without compromising accuracy. Limitations were observed: the proposed basis-function model for scattered-photon energy spectra lacks full generality across attenuation and activity distributions. Significance. This study improves the accuracy and computational efficiency of EBSE for clinically realistic activity and attenuation conditions, while clarifying scattered basis function limitations.
- Open Access
Multicenter Comparison of Radionuclide Calibrators and SPECT/CT Protocols for Quantitative 177Lu Imaging in Clinical Practice
Purpose: Following the clinical success of 177Lu-based therapies for neuroendocrine tumors and prostate cancer, accurate quantification of 177Lu using radionuclide calibrators (RNCs) and 177Lu-SPECT/CT is gaining importance as prerequisite for accurate treatment delivery and dosimetry. However, the lack of standardization can introduce inter-system variability, compromising multi-center clinical trials. This study aimed to assess the accuracy and variability of 177Lu measurements using RNCs and SPECT/CT across different systems and hospitals. Methods: A uniform cylindrical phantom and a NEMA phantom with hot spheres were prepared using traceable activities and imaged at 8 different hospitals using 13 SPECT/CT systems (9 conventional and 4 3D CZT). Acquisitions and reconstructions were performed using both site-specific and standardized protocols. The cylindrical phantom images were used to establish image calibration factors (ICFs), the NEMA images to evaluate image quality by calculating recovery coefficients (RCs). Both were used to evaluate quantitative SPECT accuracy. In parallel, two vials were measured to test RNC accuracy. Results: RNC measurements differed up to 11% between centers, while SPECT quantification differed up to 20% and 58% for the cylindrical and NEMA phantoms respectively. While ICFs were consistent for systems of the same type, image quality varied strongly when using clinical protocols. Standardized reconstruction reduced variability for each system type, regardless of acquisition protocol, but differences between system types persisted when harmonizing acquisition and reconstruction. Conclusion: Current 177Lu measurement practices yield significant variability in quantification and image quality. Harmonization efforts should prioritize standardized calibration and reconstruction protocols to improve multicenter reproducibility of quantitative 177Lu-SPECT/CT.
Open AccessMulticenter Comparison of Radionuclide Calibrators and SPECT/CT Protocols for Quantitative 177Lu Imaging in Clinical Practice
Purpose: Following the clinical success of 177Lu-based therapies for neuroendocrine tumors and prostate cancer, accurate quantification of 177Lu using radionuclide calibrators (RNCs) and 177Lu-SPECT/CT is gaining importance as prerequisite for accurate treatment delivery and dosimetry. However, the lack of standardization can introduce inter-system variability, compromising multi-center clinical trials. This study aimed to assess the accuracy and variability of 177Lu measurements using RNCs and SPECT/CT across different systems and hospitals. Methods: A uniform cylindrical phantom and a NEMA phantom with hot spheres were prepared using traceable activities and imaged at 8 different hospitals using 13 SPECT/CT systems (9 conventional and 4 3D CZT). Acquisitions and reconstructions were performed using both site-specific and standardized protocols. The cylindrical phantom images were used to establish image calibration factors (ICFs), the NEMA images to evaluate image quality by calculating recovery coefficients (RCs). Both were used to evaluate quantitative SPECT accuracy. In parallel, two vials were measured to test RNC accuracy. Results: RNC measurements differed up to 11% between centers, while SPECT quantification differed up to 20% and 58% for the cylindrical and NEMA phantoms respectively. While ICFs were consistent for systems of the same type, image quality varied strongly when using clinical protocols. Standardized reconstruction reduced variability for each system type, regardless of acquisition protocol, but differences between system types persisted when harmonizing acquisition and reconstruction. Conclusion: Current 177Lu measurement practices yield significant variability in quantification and image quality. Harmonization efforts should prioritize standardized calibration and reconstruction protocols to improve multicenter reproducibility of quantitative 177Lu-SPECT/CT.
- Open Access
Improved energy-based scatter estimation by incorporating local energy spectra and accelerating the parametric fitting
PET requires accurate, precise, and efficient scatter correction techniques. Conventional scatter estimation typically relies on tail-fitted single-scatter simulation (SSS) strategy. However, the accuracy of tail-fitted SSS is limited, for example, by mismatches between the attenuation image and the PET emission data or by the presence of activity outside the FOV. These shortcomings can be addressed using energy-based scatter estimation (EBSE), as recently proposed by Efthimiou et al. and Hamill et al. The aim of this work is to 1. improve the accuracy of EBSE by accounting for the LOR dependence of the energy spectrum of unscattered photons, 2. improve the computational speed of EBSE through better initialization and a more efficient optimization algorithm. The proposed improved EBSE method models the energy probability density function (PDF) of both single and multiple scattered photons, and incorporates a position-dependent energy PDF for unscattered photons. These energy PDFs form the basis of two forward models used for scatter estimation based on 2D energy histograms. The performance of these models were evaluated using GATE Monte Carlo simulations and a NEMA phantom acquisition on a GE SIGNA PET/MR scanner. Furthermore, we assessed the stability of EBSE across the forward models by varying the number of counts in the 2D energy histograms via data mashing. EBSE outperformed tail-fitted SSS, particularly in regions near out-of-FOV activity. Our GATE simulations showed that incorporating a local energy for unscattered photons improves off-center regional quantification by approximately 2% points. Additionally, improved initialization combined with the NEGML optimizer enabling execution on a mashed TOF sinogram in 12 minutes on six-core CPU. The proposed method enhances both the accuracy and computational efficiency of EBSE, making it well-suited for clinical applications.
Open AccessImproved energy-based scatter estimation by incorporating local energy spectra and accelerating the parametric fitting
PET requires accurate, precise, and efficient scatter correction techniques. Conventional scatter estimation typically relies on tail-fitted single-scatter simulation (SSS) strategy. However, the accuracy of tail-fitted SSS is limited, for example, by mismatches between the attenuation image and the PET emission data or by the presence of activity outside the FOV. These shortcomings can be addressed using energy-based scatter estimation (EBSE), as recently proposed by Efthimiou et al. and Hamill et al. The aim of this work is to 1. improve the accuracy of EBSE by accounting for the LOR dependence of the energy spectrum of unscattered photons, 2. improve the computational speed of EBSE through better initialization and a more efficient optimization algorithm. The proposed improved EBSE method models the energy probability density function (PDF) of both single and multiple scattered photons, and incorporates a position-dependent energy PDF for unscattered photons. These energy PDFs form the basis of two forward models used for scatter estimation based on 2D energy histograms. The performance of these models were evaluated using GATE Monte Carlo simulations and a NEMA phantom acquisition on a GE SIGNA PET/MR scanner. Furthermore, we assessed the stability of EBSE across the forward models by varying the number of counts in the 2D energy histograms via data mashing. EBSE outperformed tail-fitted SSS, particularly in regions near out-of-FOV activity. Our GATE simulations showed that incorporating a local energy for unscattered photons improves off-center regional quantification by approximately 2% points. Additionally, improved initialization combined with the NEGML optimizer enabling execution on a mashed TOF sinogram in 12 minutes on six-core CPU. The proposed method enhances both the accuracy and computational efficiency of EBSE, making it well-suited for clinical applications.
- 4 November 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (1) , 109-112
Combined brain and spinal FDG PET in the differentiation between ALS and ALS mimics – correction and additional validation study
- 4 November 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (1) , 109-112
Combined brain and spinal FDG PET in the differentiation between ALS and ALS mimics – correction and additional validation study
- 26 November 2022
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (4) , 1134-1145
[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients
Purpose Despite its limitations, [123I]MIBG scintigraphy has been the standard for human norepinephrine transporter (hNET) imaging for several decades. Recently, [18F]MFBG has emerged as a promising PET alternative. This prospective trial aimed to evaluate safety, biodistribution, tumour lesion pharmacokinetics, and lesion targeting of [18F]MFBG and perform a head-to-head comparison with [123I]MIBG in neural crest tumour patients. Methods Six neural crest tumour patients (4 phaeochromocytoma, 1 paraganglioma, 1 neuroblastoma) with a recent routine clinical [123I]MIBG scintigraphy (interval: − 37–75 days) were included. Adult patients (n = 5) underwent a 30-min dynamic PET, followed by 3 whole-body PET/CT scans at 60, 120, and 180 min after injection of 4 MBq/kg [18F]MFBG. One minor participant underwent a single whole-body PET/CT at 60 min after administration of 2 MBq/kg [18F]MFBG. Normal organ uptake (SUVmean) and lesion uptake (SUVmax; tumour-to-background ratio (TBR)) were measured. Regional distribution volumes (VT) were estimated using a Logan graphical analysis in up to 6 lesions per patient. A lesion-by-lesion analysis was performed to compare detection ratios (DR), i.e. fraction of detected lesions, between [18F]MFBG and [123I]MIBG. Results [18F]MFBG was safe and well tolerated. Its biodistribution was overall similar to that of [123I]MIBG, with prominent uptake in the salivary glands, liver, left ventricle wall and adrenals, and mainly urinary excretion. In the phaeochromocytoma subgroup, the median VT was 37.4 mL/cm3 (range: 18.0–144.8) with an excellent correlation between VT and SUVmean at all 3 time points (R2: 0.92–0.94). Mean lesion SUVmax and TBR at 1 h after injection were 19.3 ± 10.7 and 23.6 ± 8.4, respectively. All lesions detected with [123I]MIBG were also observed with [18F]MFBG. The mean DR with [123I]MIBG was significantly lower than with [18F]MFBG (61.0% ± 26.7% vs. 99.8% ± 0.5% at 1 h; p = 0.043). Conclusion [18F]MFBG is a promising hNET imaging agent with favourable imaging characteristics and improved lesion targeting compared with [123I]MIBG scintigraphy. Trial registration Clinicaltrials.gov: NCT04258592 (Registered: 06 February 2020), EudraCT: 2019-003872-37A.
- 26 November 2022
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 50 (4) , 1134-1145
[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients
Purpose Despite its limitations, [123I]MIBG scintigraphy has been the standard for human norepinephrine transporter (hNET) imaging for several decades. Recently, [18F]MFBG has emerged as a promising PET alternative. This prospective trial aimed to evaluate safety, biodistribution, tumour lesion pharmacokinetics, and lesion targeting of [18F]MFBG and perform a head-to-head comparison with [123I]MIBG in neural crest tumour patients. Methods Six neural crest tumour patients (4 phaeochromocytoma, 1 paraganglioma, 1 neuroblastoma) with a recent routine clinical [123I]MIBG scintigraphy (interval: − 37–75 days) were included. Adult patients (n = 5) underwent a 30-min dynamic PET, followed by 3 whole-body PET/CT scans at 60, 120, and 180 min after injection of 4 MBq/kg [18F]MFBG. One minor participant underwent a single whole-body PET/CT at 60 min after administration of 2 MBq/kg [18F]MFBG. Normal organ uptake (SUVmean) and lesion uptake (SUVmax; tumour-to-background ratio (TBR)) were measured. Regional distribution volumes (VT) were estimated using a Logan graphical analysis in up to 6 lesions per patient. A lesion-by-lesion analysis was performed to compare detection ratios (DR), i.e. fraction of detected lesions, between [18F]MFBG and [123I]MIBG. Results [18F]MFBG was safe and well tolerated. Its biodistribution was overall similar to that of [123I]MIBG, with prominent uptake in the salivary glands, liver, left ventricle wall and adrenals, and mainly urinary excretion. In the phaeochromocytoma subgroup, the median VT was 37.4 mL/cm3 (range: 18.0–144.8) with an excellent correlation between VT and SUVmean at all 3 time points (R2: 0.92–0.94). Mean lesion SUVmax and TBR at 1 h after injection were 19.3 ± 10.7 and 23.6 ± 8.4, respectively. All lesions detected with [123I]MIBG were also observed with [18F]MFBG. The mean DR with [123I]MIBG was significantly lower than with [18F]MFBG (61.0% ± 26.7% vs. 99.8% ± 0.5% at 1 h; p = 0.043). Conclusion [18F]MFBG is a promising hNET imaging agent with favourable imaging characteristics and improved lesion targeting compared with [123I]MIBG scintigraphy. Trial registration Clinicaltrials.gov: NCT04258592 (Registered: 06 February 2020), EudraCT: 2019-003872-37A.
- Open Access
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding and retention. The only target that is currently used in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells, including neuroendocrine tumors and neural-crest derived tumors. Academia played an important role in the development of PRRT, which has led to heterogeneous literature over the last two decades, as no standard radiopharmaceutical or regimen has been available for a long time. This review provides a summary of the treatment efficacy (e.g., response rates and symptom-relief), impact on patient outcome and toxicity profile of PRRT performed with different generations of SSTR-targeting radiopharmaceuticals, including the landmark randomized-controlled trial NETTER-1. In addition, multiple optimization strategies for PRRT are discussed, i.e., the dose–effect concept, dosimetry, combination therapies (i.e., tandem/duo PRRT, chemoPRRT, targeted molecular therapy, somatostatin analogues and radiosensitizers), new radiopharmaceuticals (i.e., SSTR-antagonists, Evans-blue containing vector molecules and alpha-emitters), administration route (intra-arterial versus intravenous) and response prediction via molecular testing or imaging. The evolution and continuous refinement of PRRT resulted in many lessons for the future development of radionuclide therapy aimed at other targets and tumor types.
Open AccessPeptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding and retention. The only target that is currently used in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells, including neuroendocrine tumors and neural-crest derived tumors. Academia played an important role in the development of PRRT, which has led to heterogeneous literature over the last two decades, as no standard radiopharmaceutical or regimen has been available for a long time. This review provides a summary of the treatment efficacy (e.g., response rates and symptom-relief), impact on patient outcome and toxicity profile of PRRT performed with different generations of SSTR-targeting radiopharmaceuticals, including the landmark randomized-controlled trial NETTER-1. In addition, multiple optimization strategies for PRRT are discussed, i.e., the dose–effect concept, dosimetry, combination therapies (i.e., tandem/duo PRRT, chemoPRRT, targeted molecular therapy, somatostatin analogues and radiosensitizers), new radiopharmaceuticals (i.e., SSTR-antagonists, Evans-blue containing vector molecules and alpha-emitters), administration route (intra-arterial versus intravenous) and response prediction via molecular testing or imaging. The evolution and continuous refinement of PRRT resulted in many lessons for the future development of radionuclide therapy aimed at other targets and tumor types.
- Open Access
- 20 February 2019
- Published by Springer Nature in EJNMMI Research
- Vol. 9 (1) , 1-21
Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization
We have developed a multi-modal imaging approach for SIRT, combining 99mTc-MAA SPECT/CT and/or 90Y PET, 18F-FDG PET/CT, and contrast-enhanced CBCT for voxel-based dosimetry, as a tool for treatment planning and verification. For radiation dose prediction calculations, a segmentation of the total liver volume and of the liver perfusion territories is required. In this paper, we proposed a procedure for multi-modal image analysis to assist SIRT treatment planning. The pre-treatment 18F-FDG PET/CT, 99mTc-MAA SPECT/CT, and contrast-enhanced CBCT images were registered to a common space using an initial rigid, followed by a deformable registration. The registration was scored by an expert using Likert scores. The total liver was segmented semi-automatically based on the PET/CT and SPECT/CT images, and the liver perfusion territories were determined based on the CBCT images. The segmentations of the liver and liver lobes were compared to the manual segmentations by an expert on a CT image. Our methodology showed that multi-modal image analysis can be used for determination of the liver and perfusion territories using CBCT in SIRT using all pre-treatment studies. The results for image registration showed acceptable alignment with limited impact on dosimetry. The image registration performs well according to the expert reviewer (scored as perfect or with little misalignment in 94% of the cases). The semi-automatic liver segmentation agreed well with manual liver segmentation (dice coefficient of 0.92 and an average Hausdorff distance of 3.04 mm). The results showed disagreement between lobe segmentation using CBCT images compared to lobe segmentation based on CT images (average Hausdorff distance of 14.18 mm), with a high impact on the dosimetry (differences up to 9 Gy for right and 21 Gy for the left liver lobe). This methodology can be used for pre-treatment dosimetry and for SIRT planning including the determination of the activity that should be administered to achieve the therapeutical goal. The inclusion of perfusion CBCT enables perfusion-based definition of the liver lobes, which was shown to be markedly different from the anatomical definition in some of the patients.
- 20 February 2019
- Published by Springer Nature in EJNMMI Research
- Vol. 9 (1) , 1-21
Open AccessMulti-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization
We have developed a multi-modal imaging approach for SIRT, combining 99mTc-MAA SPECT/CT and/or 90Y PET, 18F-FDG PET/CT, and contrast-enhanced CBCT for voxel-based dosimetry, as a tool for treatment planning and verification. For radiation dose prediction calculations, a segmentation of the total liver volume and of the liver perfusion territories is required. In this paper, we proposed a procedure for multi-modal image analysis to assist SIRT treatment planning. The pre-treatment 18F-FDG PET/CT, 99mTc-MAA SPECT/CT, and contrast-enhanced CBCT images were registered to a common space using an initial rigid, followed by a deformable registration. The registration was scored by an expert using Likert scores. The total liver was segmented semi-automatically based on the PET/CT and SPECT/CT images, and the liver perfusion territories were determined based on the CBCT images. The segmentations of the liver and liver lobes were compared to the manual segmentations by an expert on a CT image. Our methodology showed that multi-modal image analysis can be used for determination of the liver and perfusion territories using CBCT in SIRT using all pre-treatment studies. The results for image registration showed acceptable alignment with limited impact on dosimetry. The image registration performs well according to the expert reviewer (scored as perfect or with little misalignment in 94% of the cases). The semi-automatic liver segmentation agreed well with manual liver segmentation (dice coefficient of 0.92 and an average Hausdorff distance of 3.04 mm). The results showed disagreement between lobe segmentation using CBCT images compared to lobe segmentation based on CT images (average Hausdorff distance of 14.18 mm), with a high impact on the dosimetry (differences up to 9 Gy for right and 21 Gy for the left liver lobe). This methodology can be used for pre-treatment dosimetry and for SIRT planning including the determination of the activity that should be administered to achieve the therapeutical goal. The inclusion of perfusion CBCT enables perfusion-based definition of the liver lobes, which was shown to be markedly different from the anatomical definition in some of the patients.
- Open Access
- 17 April 2018
- Published by Springer Nature in EJNMMI Research
- Vol. 8 (1) , 34
On the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone
In epilepsy patients, SISCOM or subtraction ictal single photon emission computed tomography co-registered to magnetic resonance imaging has become a routinely used, non-invasive technique to localize the ictal onset zone (IOZ). Thresholding of clusters with a predefined number of standard deviations from normality (z-score) is generally accepted to localize the IOZ. In this study, we aimed to assess the robustness of this parameter in a group of patients with well-characterized drug-resistant epilepsy in whom the exact location of the IOZ was known after successful epilepsy surgery. Eighty patients underwent preoperative SISCOM and were seizure free in a postoperative period of minimum 1 year. SISCOMs with z-threshold 2 and 1.5 were analyzed by two experienced readers separately, blinded from the clinical ground truth data. Their reported location of the IOZ was compared with the operative resection zone. Furthermore, confidence scores of the SISCOM IOZ were compared for the two thresholds. Visual reporting with a z-score threshold of 1.5 and 2 showed no statistically significant difference in localizing correspondence with the ground truth (70 vs. 72% respectively, p = 0.17). Interrater agreement was moderate (κ = 0.65) at the threshold of 1.5, but high (κ = 0.84) at a threshold of 2, where also reviewers were significantly more confident (p < 0.01). SISCOM is a clinically useful, routinely used modality in the preoperative work-up in many epilepsy surgery centers. We found no significant differences in localizing value of the IOZ using a threshold of 1.5 or 2, but interrater agreement and reader confidence were higher using a z-score threshold of 2.
- 17 April 2018
- Published by Springer Nature in EJNMMI Research
- Vol. 8 (1) , 34
Open AccessOn the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone
In epilepsy patients, SISCOM or subtraction ictal single photon emission computed tomography co-registered to magnetic resonance imaging has become a routinely used, non-invasive technique to localize the ictal onset zone (IOZ). Thresholding of clusters with a predefined number of standard deviations from normality (z-score) is generally accepted to localize the IOZ. In this study, we aimed to assess the robustness of this parameter in a group of patients with well-characterized drug-resistant epilepsy in whom the exact location of the IOZ was known after successful epilepsy surgery. Eighty patients underwent preoperative SISCOM and were seizure free in a postoperative period of minimum 1 year. SISCOMs with z-threshold 2 and 1.5 were analyzed by two experienced readers separately, blinded from the clinical ground truth data. Their reported location of the IOZ was compared with the operative resection zone. Furthermore, confidence scores of the SISCOM IOZ were compared for the two thresholds. Visual reporting with a z-score threshold of 1.5 and 2 showed no statistically significant difference in localizing correspondence with the ground truth (70 vs. 72% respectively, p = 0.17). Interrater agreement was moderate (κ = 0.65) at the threshold of 1.5, but high (κ = 0.84) at a threshold of 2, where also reviewers were significantly more confident (p < 0.01). SISCOM is a clinically useful, routinely used modality in the preoperative work-up in many epilepsy surgery centers. We found no significant differences in localizing value of the IOZ using a threshold of 1.5 or 2, but interrater agreement and reader confidence were higher using a z-score threshold of 2.